Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 studyBrian G. Feagan, Wulf O. Böcher, Édouard Louis et al.|The Lancet|2017Cited by 449
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension studyBrian G. Feagan, Wulf O. Böcher, Julián Panés et al.|The Lancet. Gastroenterology & hepatology|2018Cited by 157
812a Efficacy and Safety of Induction Therapy With the Selective IL-23 Inhibitor BI 655066, in Patients With Moderate-to-Severe Crohn's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II StudyBrian G. Feagan, Wulf O. Böcher, William J. Sandborn et al.|Gastroenterology|2016Cited by 14